A retrospective study of DRESS – drug reaction with eosinophilia and systemic symptoms

Mehrholz, Dorota; Urbán, A; Herstowska, Marta; Nowicki, Roman; Cubała, Wiesław Jerzy; Barańska‐Rybak, Wioletta

doi:10.12740/pp/74358

Cited by 10 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug‐induced hypersensitivity syndrome is a severe drug eruption associated with rash along with high fever, organ dysfunction (e.g., liver), and lymphadenopathy. 1 , 2 , 3 It is characterized by prolonged symptoms even after discontinuation of the causative drug. DiHS is known as DRESS in Europe.…”

Section: Discussionmentioning

confidence: 99%

“…It is characterized by prolonged symptoms even after discontinuation of the causative drug. DiHS is known as DRESS in Europe 1–3 …”

Section: Discussionmentioning

confidence: 99%

“…DiHS is known as DRESS in Europe. [1][2][3] A diagnosis of atypical DiHS or DRESS was made for case 3 because HHV-6 reactivation was not detected. However, we thought that the timing of examination was inappropriate.…”

Section: Casementioning

confidence: 99%

See 2 more Smart Citations

Three cases of drug‐induced hypersensitivity syndrome associated with mRNA‐based coronavirus disease 2019 vaccines

Korekawa

Nakajima

Fukushi

et al. 2022

The Journal of Dermatology

View full text Add to dashboard Cite

Drug‐induced hypersensitivity syndrome (DiHS) is a severe drug eruption that can induce reactivation of herpesviruses such as human herpesvirus 6, resulting in symptom flare‐up and organ damage. DiHS is known as drug reaction with eosinophilia and systemic symptoms (DRESS) in Europe. We report three cases of DiHS that could have been triggered by mRNA‐based coronavirus disease 2019 (COVID‐19) vaccines. In these three patients, symptoms of DiHS developed 2–6 days after the first dose of an mRNA‐based COVID‐19 vaccine. Although there have been no reports of DiHS/DRESS induced by mRNA‐based COVID‐19 vaccines in domestic and international journals despite the progress in vaccination worldwide, we speculate that mRNA‐based COVID‐19 vaccines might have triggered the development of DiHS/DRESS in our patients. In the current coronavirus epidemic, it might be important to assess mRNA‐based COVID‐19 vaccination status and date of vaccination when evaluating a patient with DiHS/DRESS.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It is characterized by prolonged symptoms even after discontinuation of the causative drug. DiHS is known as DRESS in Europe 1–3 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Three cases of drug‐induced hypersensitivity syndrome associated with mRNA‐based coronavirus disease 2019 vaccines

Korekawa

Nakajima

Fukushi

et al. 2022

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Drug reaction with eosinophilia and systemic symptoms (DRESS) is a syndrome that can involve the skin and visceral organs, and its complications can lead to organ failure and even death. 1 This is a rare drug reaction with a prolonged latency between first exposure to the offending drug and onset of symptoms. 2 Therefore, an unexplained multisystemic disease warrants prompt diagnostic re-assessment, and drugs seem to be the most common culprit in such circumstances.…”

Section: Etiologymentioning

confidence: 99%

How to recognize and manage challenging DRESS cases: Two case reports and a review of the literature

Erdem

Durmuş

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is an uncommon systemic adverse drug reaction. Furthermore, it is a unique syndrome encompassing various manifestations of fever, facial edema, eosinophilia, atypical lymphocytosis, and organ dysfunction. Since there are no large prospective studies concerning DRESS syndrome, current treatment modalities for DRESS have been mainly determined based on various case reports and expert opinions. Corticosteroids are the mainstay of therapy after the cessation of the culprit drug. Although most cases recover within a couple of months, some may persist and even progress despite 1 mg/kg/day of prednisolone or its equivalent. We herein present two cases of severe DRESS syndrome. Both cases presented with organ dysfunction and remained unresponsive to initial treatment with 1 mg/kg/day of intravenous methylprednisolone. Therefore, plasmapheresis or pulse steroid therapy (250 mg/day methylprednisolone for 3 days) was used. In the follow-up period, the patients' clinical conditions improved dramatically without recurrence. We aimed to share our experience in recognizing and managing severe DRESS cases in this manuscript. Furthermore, we reviewed the literature in comparison with the present cases. In conclusion, plasmapheresis or pulse steroid therapy (250 mg/day of methylprednisolone for 3 days) can be used to treat difficult DRESS cases where organ failure is about to happen.

show abstract

Maculopapular rash in brown skin

Allen,

Co,

Kellar

et al. 2023

JACEP Open

View full text Add to dashboard Cite

A retrospective study of DRESS – drug reaction with eosinophilia and systemic symptoms

Abstract: DRESS diagnosis should be taken into consideration especially in patients treated eith antiepileptic drugs. Early diagnosis and drug discontinuation can contribute to preventing serious complications of DRESS.

Cited by 10 publications

References 23 publications

Three cases of drug‐induced hypersensitivity syndrome associated with mRNA‐based coronavirus disease 2019 vaccines

Three cases of drug‐induced hypersensitivity syndrome associated with mRNA‐based coronavirus disease 2019 vaccines

How to recognize and manage challenging DRESS cases: Two case reports and a review of the literature

Maculopapular rash in brown skin

Contact Info

Product

Resources

About